A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2020-02-18
Target enrollment:
Participant gender:
Summary
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked
(blinded) study designed to explore efficacy of ORMD-0801 when given in different regimens
across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).